JPS5772920A - Carcinostatic agent containing blood plasma or blood serumal lipoprotein - Google Patents

Carcinostatic agent containing blood plasma or blood serumal lipoprotein

Info

Publication number
JPS5772920A
JPS5772920A JP55149441A JP14944180A JPS5772920A JP S5772920 A JPS5772920 A JP S5772920A JP 55149441 A JP55149441 A JP 55149441A JP 14944180 A JP14944180 A JP 14944180A JP S5772920 A JPS5772920 A JP S5772920A
Authority
JP
Japan
Prior art keywords
lipoprotein
blood
blood plasma
serumal
specific gravity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP55149441A
Other languages
Japanese (ja)
Other versions
JPH0140810B2 (en
Inventor
Hiroshi Kodama
Masao Nakabayashi
Yoshifumi Nakajima
Takashi Nagai
Toshiyuki Matsukawa
Masaaki Shibata
Takashi Sano
Isao Myokan
Tetsuya Kajita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toyama Chemical Co Ltd
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Priority to JP55149441A priority Critical patent/JPS5772920A/en
Publication of JPS5772920A publication Critical patent/JPS5772920A/en
Publication of JPH0140810B2 publication Critical patent/JPH0140810B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

PURPOSE: A carcinostatic agent, containing a blood plasma or blood serumal lipoprotein with almost no side effects.
CONSTITUTION: The concentration of a blood plasma or blood serumal lipoprotein is adjusted to an optimal value of 1/100W10 times according to the purpose to give a carcinostatic agent in the form of an injection, etc. A lipoprotein derived from a man, particularly a healthy man, is preferred, and the lipoprotein can be separated from the blood plasma or blood serum by the methods, e.g. the gel filtration, ultracentriguation, electroresist or precipitation. The respectve fractions of the separated lipoprotein contain chylomicron a very low specific gravity lipoprotein (VLDL), low specific gravity lipoprotein (LDL), high specific gravity lipoprotein (HLD), ultrahigh specific gravity lipoprotein (LHDL), and particularly LDL and HLD are preferred. Various lipoprotein pharmaceuticals in a dose corresponding to the lipoprotein contained in 1W200Ml blood plasma or blood serum of a healthy man are preferably administered parenterally or orally one W several times a day for an adult.
COPYRIGHT: (C)1982,JPO&Japio
JP55149441A 1980-10-27 1980-10-27 Carcinostatic agent containing blood plasma or blood serumal lipoprotein Granted JPS5772920A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP55149441A JPS5772920A (en) 1980-10-27 1980-10-27 Carcinostatic agent containing blood plasma or blood serumal lipoprotein

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP55149441A JPS5772920A (en) 1980-10-27 1980-10-27 Carcinostatic agent containing blood plasma or blood serumal lipoprotein

Publications (2)

Publication Number Publication Date
JPS5772920A true JPS5772920A (en) 1982-05-07
JPH0140810B2 JPH0140810B2 (en) 1989-08-31

Family

ID=15475178

Family Applications (1)

Application Number Title Priority Date Filing Date
JP55149441A Granted JPS5772920A (en) 1980-10-27 1980-10-27 Carcinostatic agent containing blood plasma or blood serumal lipoprotein

Country Status (1)

Country Link
JP (1) JPS5772920A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0366277A2 (en) * 1988-09-29 1990-05-02 Patralan Limited Pharmaceutical formulations

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0366277A2 (en) * 1988-09-29 1990-05-02 Patralan Limited Pharmaceutical formulations
US5656289A (en) * 1988-09-29 1997-08-12 Patralan Limited Pharmaceutical formulations that have a biologically active hydrophilic phase and a chylomicra-containing hydrophobic phase

Also Published As

Publication number Publication date
JPH0140810B2 (en) 1989-08-31

Similar Documents

Publication Publication Date Title
Makowske et al. Contrasts in transport systems for anionic amino acids in hepatocytes and a hepatoma cell line HTC.
ES8500060A1 (en) Stabilized insulin preparations
ES8403025A1 (en) Stabilized insulin preparations and a process for preparation thereof
GB2124079B (en) Process for prolonging retention of emulsion particles in the bloodstream
ES2177796T3 (en) EXTRACTION BY SOLVENT OF POLYHYDROXIALCANOATS FROM BIOMASSFACILITATED BY THE USE OF A MARGINAL NON-SOLVENT FOR PHA.
EP0319557A4 (en) Reconstituted hdl particles and uses thereof
MA22915A1 (en) METHODS OF TREATING OSTEOPOROSIS FOR THE USE OF LOW DOSES OF PHOSPHONATES.
FR2437834A1 (en) L-serine or glycine for treatment of cerebral deficiencies - such as mongolism and general mental debility, etc.
HUT63863A (en) Complex comprising anticoagulant ix factor
ES485640A1 (en) Process for the preparation of cold-insoluble globulin and medicament containing it.
JPS5228947A (en) Oral remedy for hyperlipemia
JPS5772920A (en) Carcinostatic agent containing blood plasma or blood serumal lipoprotein
Burge et al. Inhibition of the alternative pathway of complement by gold sodium thiomalate in vitro
GB2050833A (en) Pharmaceutical compositions and process for the preparation thereof
Steele et al. Lipoprotein interaction with artery wall derived proteoglycan: comparisons between atherosclerosis-susceptible WC-2 and resistant Show Racer pigeons
EP0652755A1 (en) Therapeutic use of phosphoryl-l-serine-n-acyl-sphingosine.
DeLisi et al. P-chlorophenylalanine trials in schizophrenic patients.
IL101908A (en) Process for extraction of antineoplastic substances from plants of the family pittosporaceae, extracts obtained thereby, and pharmaceutical preparations containing them
Cronholm et al. Decrease in arachidonoyl-containing phosphatidylinositols in pancreas of rats fed an ethanol-containing diet
FR2570503B1 (en) DEVICE FOR SEPARATING PLASMA FROM THE OTHER CONSTITUENTS OF A BLOOD LIQUID
ES8609363A1 (en) Fractionation of blood plasma
ES2019017A6 (en) Process for separation and concentration of apolipoproteins.
JPS56127307A (en) Blood-coagulation factor 8 pharmaceutical for oral administration
NZ334634A (en) Use of a protein extracted from mammalian liver for treating HIV
JPS51120054A (en) Apparatus for separating solid matter and liquid from mud